All In Biotech

Drug Trial Radar · NCT07694544

Renal Impairment Study for Oral EC5026

Assessment of Single Dose Pharmacokinetics of Oral EC5026 in a Population With Chronic Kidney Disease

Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Jul 1, 2026

Primary completion

Dec 31, 2026

Study completion Jun 30, 2027

Sponsor

Lead sponsor
EicOsis Human Health Inc.Industry
Sponsor type
Industry
First posted
Jul 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this Phase 1 clinical trial is to assess single dose pharmacokinetics of oral EC5026 in a population with chronic kidney disease. The main questions it aims to answer are: 1. To determine if the PK of a single 8 mg dose of EC5026, administered orally, in adult participants with varying severity of CKD differs from age-matched healthy participants with normal kidney function. 2. To determine if a single 8 mg dose of EC5026, administered orally, in adult participants with varying severity of CKD is safe and well tolerated. Researchers will compare a single 8 mg dose of oral across participants with varying degrees of kidney function impairment (either normal kidney function, or stage 3b chronic kidney disease \[CKD\], or state 4/5 CKD). Participants will be asked to take a single oral dose of EC5026 and will be monitored with PK laboratory assessments and safety assessments (including physical exams, vital signs, electrocardiograms, and others).

Conditions

  • Chronic Kidney Disease

Interventions

  • EC5026 oral tabletDrug

    Oral 8 mg EC5026 tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC0-t)Time frame: 14 days
  2. Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC0-∞)Time frame: 14 days
  3. Maximum observed plasma concentration (Cmax)Time frame: 14 days
  4. Time to the maximum observed concentration of the drug (Tmax)Time frame: 14 days
  5. Apparent terminal elimination rate constant (Kel)Time frame: 14 days
  6. Terminal elimination half-life of the drug (t½).Time frame: 14 days
  7. Apparent clearance (CL/F).Time frame: 14 days
  8. Apparent volume of distribution during the terminal phase (Vz/F)Time frame: 14 days
  9. Renal clearance (CLR)Time frame: 48 hours
  10. Amount of unchanged drug excreted in urine (Ae).Time frame: 48 hours
  11. Fraction of eliminated dose (Fe%)Time frame: 48 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UC Davis Medical Center

    Sacramento, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.